Table 1 Patients’ characteristics according to the AC (doxorubicin and cyclophosphamide) regimen (N = 311)
Every 3-week AC (n = 130) | Dose-dense AC (n = 181) | P-value | |
|---|---|---|---|
Age, years | 0.119a | ||
Median (Range) | 44 (24–79) | 42 (23–83) | |
Histology, N (%) | 0.810b | ||
Ductal | 115 (93.5%) | 163 (93.1%) | |
Lobular | 3 (2.4%) | 3 (1.7%) | |
Other | 5 (4%) | 9 (5.1%) | |
Grade | 0.552b | ||
1 | 1 (0.7%) | 2 (1.1%) | |
2 | 22 (17%) | 27 (14.9%) | |
3 | 89 (68.9%) | 136 (75.1%) | |
NA | 17 (13.1%) | 16 (8.8%) | |
Estrogen receptor | 0.592b | ||
Negative | 122 (93.8%) | 172 (95%) | |
1–10% | 7 (5.3%) | 9 (4.9%) | |
Progesterone receptor | 0.528b | ||
Negative | 126 (96.9%) | 178 (98.3%) | |
1–10% | 3 (2.3%) | 3 (1.6%) | |
Ki67 index, N (%) | 0.102b | ||
<50% | 30 (25.4%) | 29 (16.8) | |
≥50% | 88 (74.5%) | 143 (83.1) | |
TILs | 0.329b | ||
<30% | 44 (33.8%) | 59 (32.6%) | |
≥30% | 12 (9.2%) | 27 (14.9%) | |
NA | 74 (56.9%) | 95 (52.5%) | |
BRCA1/2 results available | 88 (67.6%) | 157 (86.7%) | - |
BRCA1/2 | 0.850b | ||
Mutated | 13 (15.1%) | 22 (14.1%) | |
Wild-type | 73 (84.8%) | 134 (85.9%) | |
T stage | 0.356b | ||
Tx | 4 (3.1) | 2 (1.1%) | |
T1 | 9 (7.7%) | 16 (8.8%) | |
T2 | 76 (59.3%) | 124 (68.8%) | |
T3 | 28 (21.8%) | 29 (16.1%) | |
T4 | 10 (7.8%) | 9 (5%) | |
N stage | 0.803b | ||
N0 | 63 (48.8%) | 94 (52.2%) | |
N1(mic) | 0 (0%) | 1 (0.5%) | |
N1 | 43 (33.3%) | 54 (30%) | |
N2 | 12 (9.3%) | 14 (7.7%) | |
N3 | 10 (7.7%) | 17 (9.4%) | |
Anatomic Stage | 0.701b | ||
I | 3 (2.3%) | 6 (3.2%) | |
IIA | 61 (47.6) | 100 (55.5%) | |
IIB | 25 (19.5%) | 27 (15%) | |
IIIIA | 25 (19.5%) | 27 (15%) | |
IIIB | 5 (3.9%) | 5 (2.7%) | |
IIIC | 9 (7%) | 15 (8.3%) | |
BMI | 0.613a | ||
Median (range) | 25.9 (19.1–43.1) | 26.2 (16.9–47.2) | |
Menopausal status | 0.591b | ||
Premenopausal | 78 (60%) | 120 (66.3%) | |
Postmenopausal | 42 (32.3%) | 52 (28.7%) | |
NA | 10 (7.6%) | 9 (4.9%) |
